PEDIATRICS Vol. 76 No. 4 October 1985, pp. 652
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SCHICK, J. B.
Right arrow Articles by GOETZMAN, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SCHICK, J. B.
Right arrow Articles by GOETZMAN, B. W.

Chronic Lung Disease of Prematurity

JAMES B. SCHICK MD1 and BOYD W. GOETZMAN MD, PhD2

1 Department of Pediatrics, Saint Francis Hospital and Medical Center, 114 Woodland St, Hartford, CT 06105
2 Division of Neonatology, TB 193, University of California, Davis, CA 95616

To the Editor.—

The paper by Avery et al,1 further demonstrates the potential usefulness of corticosteroids in chronic lung disease of prematurity. However, initial reports in 1974 and 1975 met with criticism for the use of potentially toxic drugs in premature infants.2,3

In 1983 we retrospectively reviewed 23 infants with chronic lung disease of prematurity who received corticosteroids and identified distinct differences between responders and nonresponders which suggested different types of lung disease.4 Our responders all showed a greater than 30% decrease in AaPo2 by day 6 and showed maximal response by ten days of therapy.